Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 3.15 20,510 13:29:25
Bid Price Offer Price High Price Low Price Open Price
2.82 3.50 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.41 -1.66 -0.44 9
Last Trade Time Trade Type Trade Size Trade Price Currency
10:12:52 O 5,500 2.854 GBX

Proteome Sciences (PRM) Latest News (4)

More Proteome Sciences News
Proteome Sciences Takeover Rumours

Proteome Sciences (PRM) Discussions and Chat

Proteome Sciences Forums and Chat

Date Time Title Posts
30/3/202013:24Proteome Sciences leading Alzheimer's technology.85,129
30/3/202011:56Proteome, what next? (moderated)55,532
10/2/202000:17Proteome Sciences plc, A Three Horse Race for the Month of May.4,852
02/7/201917:54The useful PRM thread13
13/2/201918:56The 2008 PRM Golf Day Thread39

Add a New Thread

Proteome Sciences (PRM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Proteome Sciences trades in real-time

Proteome Sciences (PRM) Top Chat Posts

Proteome Sciences Daily Update: Proteome Sciences Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 3.15p.
Proteome Sciences Plc has a 4 week average price of 2.98p and a 12 week average price of 2.70p.
The 1 year high share price is 4.30p while the 1 year low share price is currently 2.35p.
There are currently 294,648,723 shares in issue and the average daily traded volume is 42,541 shares. The market capitalisation of Proteome Sciences Plc is £9,281,434.77.
ih_433513: Re Randox stroke test - due to be launched imminently in Q4 2019. Still no UCH validation, still no EU CE Mark, still no comment of any sort from PRM, still no comment from senior board members about PRM’s Stroke patents expiring in 2020. And the share price still at 3p despite the always right fake doc saying 10p by Dec 2018. What a palaver eh.
jamtomorrow2: Doc - massive dilution caused by reduced share price giving CJP a ridiculously high conversion rate on his convertible loans. Please don’t embarrass yourself further by arguing that the massive losses haven’t caused the low share price.
canaletto: Richard, I had lunch with you, your dear wife, along with "Peter Snodgrass"and "Freelance". This was years ago and Prm share price was £1.52. Do you not think that the moron is you considering what you and "Peter" collectively said, and what I learned from Peter and one of his daughters subsequent before his passing? Just saying?
dunderheed: I totally totally reject the above theories. I think there are a lot of "things" going on behind the scenes, many furtive telephone calls between pharma companies and posters on here, many important phone calls and e mails between the privileged members of PRM inter net "ring" and lastly of course, 're jigging of £54 share price schedule spread sheets in preparation for the sudden surge in share price to 10p prior to end of year. I am waiting excitedly.
canaletto: I am pretty damn sure Haigh wasn't booted out and I'd bet he couldn't leave quick enough once the penny dropped that Prm was very different to the company he was led to believe it was. However isn't one of the goals to increase the share price year on year? At least keep pace with the market? Dow Jones when he joined was 14,000. Now it is 28,000 and rising. Prm was 17.9p and now it is 3p. He has been paid a tad shy of £1m for this. It's not my job to suggest strategy. All I know is that he oversaw a spectacular decline in the share price.
jeffian: Ahem! up10 - 07 Oct 2019 - 14:29:11 - 83560 of 83609 Proteome Sciences leading Alzheimer's technology. - PRM Hi Pools2, Randox did say that they were very happy with the Stroke Biochip results. BUY BUY BUY up10 - 07 Oct 2019 - 12:59:04 - 83556 of 83609 Proteome Sciences leading Alzheimer's technology. - PRM I spoke with a Randox representative this morning and they told me the CE marking of the Stroke Biochip is nearly complete. The validated clinical version of the Stroke Biochip and CE marked should be available by the end of this year. BUY BUY BUY up10 - 25 Jul 2019 - 09:36:19 - 83062 of 83609 Proteome Sciences leading Alzheimer's technology. - PRM Good performance in H1 2019, with more in H2 as usual. With all of the new product royalties, milestones and license fees due, Proteome Sciences will easily be profitable next year. BUY BUY BUY up10 - 24 Jul 2019 - 11:30:43 - 83005 of 83609 Proteome Sciences leading Alzheimer's technology. - PRM The past is history. As you say, there is a big opportunity to acquire stock now at historic low levels. In my view, it's a "no brainer" as quite clearly revenue is about to take off. Get on board now, before everyone else. BUY BUY BUY up10 - 03 Jul 2019 - 16:04:50 - 82693 of 83609 Proteome Sciences leading Alzheimer's technology. - PRM It's there for everyone to see on the Randox website, yet most investors seem to be in denial until PRM announce something themselves! Weird behaviour. Get in quick before they do! BUY BUY BUY up10 - 30 Jun 2019 - 12:43:33 - 82577 of 83609 Proteome Sciences leading Alzheimer's technology. - PRM pools2 You're right of course, it is incorrect to assume the "double digit" royalty is only 10%. My experience with US diagnostic companies suggests it is far higher. We are entering a very exciting period for Proteome Sciences as many further Stroke licences will be signed, with accelerating revenues for PRM. Then add the new 16-plex TMT reagents, Clusterin Glycoform test and Tryptophan Metabolite test products, investors have a significant investment opportunity at these ridiculously low share price levels. BUY BUY BUY up10 - 15 Apr 2019 - 11:15:02 - 82360 of 83609 Proteome Sciences leading Alzheimer's technology. - PRM The lull before the storm. Last Friday, Proteome (PRM) hit an upwards 5 year price breakout. BUY BUY BUY
jeffian: Blimey, say! Quite a few lessons to be learned there but this one caught my eye in particular - "He listed some of the difficulties ahead, and indicated that he considered the PRM share price already to be too high. I started to write out an answer to all his points. But I suddenly remembered a lesson I learned many years ago – that it is not wise to argue with a scientist. So I gave up the task and just simply bought more PRM shares instead."
ih_433513: Happy 10 year anniversary wasJobber. You were a busy boy! wasjobber - 02 Jul 2008 - 22:49:36 - 3909 of 16188 Proteome Sciences - from research to revenue in 07 - PRM The reasons and terms of cjp's loan to the company are being twisted out of all proportion on this bb to benefit the bashers/shorters positions. Most if not all comments on here relating to this and many other issues are false! wasjobber - 02 Jul 2008 - 20:52:20 - 36923 of 54056 Proteome, what next? (moderated) - PRM monte1 So thats your only reason to continually bash the stock and try to cause weaker holders to sell is it? It's not logical i'm afraid to be selling prm when they are at last on the cusp of generating significant revenue. It's pathetic to try and kid people you own prm stock yourself by the way. wasjobber - 02 Jul 2008 - 20:06:23 - 36920 of 54056 Proteome, what next? (moderated) - PRM monte1 As you seem to be one of the more vocal bashers on here, maybe you can tell me how the company is in a poorer situation now than say 1 or 2 years ago? With the Thermo deal done (providing growing income) and other deals now much closer! wasjobber - 02 Jul 2008 - 17:32:09 - 36916 of 54056 Proteome, what next? (moderated) - PRM Funny how the bashers go so quiet after office hours. wasjobber - 02 Jul 2008 - 17:29:43 - 36915 of 54056 Proteome, what next? (moderated) - PRM the_doctor, Sorry but that simply doesn't make sense to me! PRM are in a far far better position now, even with £6m debt. Which of course will be wiped out by cjp converting or other income. wasjobber - 02 Jul 2008 - 17:14:15 - 36911 of 54056 Proteome, what next? (moderated) - PRM I suppose my last post is just far to sensible for most people on here. wasjobber - 02 Jul 2008 - 17:06:12 - 36909 of 54056 Proteome, what next? (moderated) - PRM loftybob, I'm refering to the_doctor answering my earlier question! The situation now is far better now than 1 or 2 years ago! Massive Thermo deal, other huge prospects. If the situation is worse now then please explain, because i can't see it! wasjobber - 02 Jul 2008 - 16:59:23 - 36906 of 54056 Proteome, what next? (moderated) - PRM the_doctor ? wasjobber - 02 Jul 2008 - 16:45:38 - 36899 of 54056 Proteome, what next? (moderated) - PRM the_doctor I must be very stupid. Why is the company any more like to go bust now than say 1 or 2 years ago? Pearce is very happy to fund the company until it is in profit! wasjobber - 02 Jul 2008 - 16:18:11 - 36889 of 54056 Proteome, what next? (moderated) - PRM dwschag, Some sense on here at last! wasjobber - 02 Jul 2008 - 16:03:08 - 36878 of 54056 Proteome, what next? (moderated) - PRM loafingchard, I'm here and a raging bull, BUY, BUY, BUY. The share price is just bloody silly. wasjobber - 02 Jul 2008 - 12:57:57 - 36784 of 54056 Proteome, what next? (moderated) - PRM;cb=1214999844&article=7325098&symbol=L%5EPRM wasjobber - 02 Jul 2008 - 12:52:57 - 36781 of 54056 Proteome, what next? (moderated) - PRM Thermo will be bidding shortly, just watch! wasjobber - 02 Jul 2008 - 11:31:51 - 36763 of 54056 Proteome, what next? (moderated) - PRM Bid coming! wasjobber - 02 Jul 2008 - 09:30:09 - 36730 of 54056 Proteome, what next? (moderated) - PRM silentaction, PRM won't go like that, it's impossible with CJP's protection of IP.
saul goodman: Hahahahahaha - I note that it is 1999 all over again on iii! 10:36 John Hopkins Cancer Test "breakthrough"...i network This present news headline sounds like it depends on proteomics tests as well as genetic tests. I would think this could have significant impact on proteomic testing sales and services/ Why is this not affecting PRM share price?? ---------------------------------------------------------------------------------- 12:30 Hold Re: John Hopkins Cancer Test The Potter I also recently read an article on Sepsis, where biomarkers were found to give the best indication of the presence of this illness. I suppose that the share price Is unaffected by these news items, because many investors do not understand the possible implications, and those that do, are awaiting for news of profitability (promised in 2018). TP
pools2: With Proteome Sciences now a GCLP accredited company, many many more doors are now open to them, which were firmly closed before. Do not underestimate the significance of the new accreditation and the additional business it will bring. PRM share price will go up and up from this current level. No additional funding will be needed and the company will be in profit next year.
Proteome Sciences share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Proteome S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200330 13:33:04